Profiling of Phospho-AKT, Phospho-mTOR, Phospho-MAPK and EGFR in Non-small Cell Lung Cancer. (May 2014)

• Record Type: Journal Article
• Authors: Kitano, Haruhisa; Chung, Joon-Yong; Ylaya, Kris; Conway, Catherine; Takikita, Mikiko; Fukuoka, Junya; Doki, Yoshinori; Hanaoka, Jun; Hewitt, Stephen M.
• Is Part Of: Journal of histochemistry and cytochemistry. Volume 62:Number 5(2014:May)
• Page Start: 335
• Page End: 346
• Publication Date: 2014-05
• Subjects: AKT -- EGFR -- Image analysis -- Immunohistochemistry -- MAPK -- mTOR -- Non-small cell lung cancer -- Survival analysis -- Tissue microarray; Histochemistry -- Periodicals; Cytochemistry -- Periodicals; Histocytochemistry -- methods; Histological Techniques; 572.05
• DOI: 10.1369/0022155414523022
• Languages: English
• ISSNs: 0022-1554

Abstract

Activation of numerous pathways has been documented in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) has emerged as a common therapeutic target. The mitogen-activated protein kinase (MAPK) and AKT signaling pathways are downstream of EGFR and deregulated via genetic and epigenetic mechanisms in many human cancers. We evaluated selected markers in the EGFR pathway with reference to outcome. Tissues from 220 cases of NSCLC patients presented in a tissue microarray were assayed with immunohistochemistry for phosphorylated AKT, phosphorylated MAPK, phosphorylated mTOR, and EGFR and then quantified by automated image analysis. Individually, the biomarkers did not predict. Combined as ratios, p-mTOR/p-AKT, and p-MAPK/EGFR function as prognostic markers of survival ( p =0.008 and p =0.029, respectively), however, no significance was found after adjustment ( p =0.221, p =0.103). The sum of these ratios demonstrates a stronger correlation with survival ( p <0.001) and remained statistically significant after adjustment ( p =0.026). The algebraic combination of biomarkers offer the capacity to understand factors that predict outcome better than current approaches of evaluating biomarkers individually or in pairs. Our results show the sum of p-mTOR/p-AKT and p-MAPK/EGFR is a potential predictive marker of survival in NSCLC patients.